drugset / Trial / NCT02514031
ARQ-761 Treatment With Gemcitabine/Nab-Paclitaxel Chemotherapy In Pancreatic Cancer
NaSingle-groupOpen-labelOther
Summary
This is a study of ARQ-761 (beta-lapachone) with gemcitabine/nab-paclitaxel chemotherapy in subjects with advanced (metastatic, unresectable, or recurrent) pancreatic cancer that has not been treated with gemcitabine.
Timeline
- Start
- 2016-03-24
- Primary completion
- 2018-05-22
- Completion
- 2022-05
Outcome
Outcome not reported
Stopped (Enrollment): “The study placed on temporarily hold to enrollment due to quality testing necessary for the study drug.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ARQ761 | Small molecule | 195 mg | Intravenous |
| Subject | ARQ761 | Small molecule | 290 mg | Intravenous |
| Subject | ARQ761 | Small molecule | 390 mg | Intravenous |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Background | Nab-paclitaxel | Small molecule | 125 mg/m2 | Intravenous |